Image of Guardian™ Connect system, i-Port Advance™
injection port and InPen™ smart insulin pen

Smart MDI: CGM + smart insulin pen system


For people who manage their diabetes with insulin injections, the Smart MDI system can help relieve the physical and mental effort required, by using an ecosystem of smart-enabled technology devices, to help make life a bit easier.

The Smart MDI system includes a continuous glucose monitor (CGM), an injection port, and smart insulin pen.

For people living with type 1 or type 2 diabetes, we have tools to help you stay ahead.


Discover more today!

Ask more of your CGM

See how much more it can do as part of a system

Combine these three powerful tools that can help you stay ahead of diabetes



Guardian
Connect system


Image of the Guardian™ Connect system showing a sensor and smart phone with app screen


Do high sugar levels have you down?


Get ahead of your highs
The only continuous glucose monitor (CGM) that can predict a high or low up to an hour in advance.*

  • Easy-to-use app
  • Small sensor & transmitter
  • Automatic uploads

Learn how different foods & activities affect your sugars in real time

InPen
smart insulin pen


Image of the InPen™ smart insulin pen system showing a smart phone with app screen, bluetooth symbol and blue InPen with the cap off


Did you forget to dose?


The right dose at the right time
Bluetooth® enabled smart pen that does the math and logs doses for you.

  • Calculates insulin doses
  • Offers dose reminders
  • Delivers half unit doses
  • Monitors insulin temperature

Get personalized dosing recommendations

i-Port Advance
injection port


Image of the i-Port Advance™ injection port


Want to reduce needle pokes?


It takes the shots for you
Deliver your insulin injections without having to puncture your skin for each shot.

  • 1 poke every 3 days
  • Simple to apply and easy to use

93% reduction in needle pokes**

Image of Medtronic Smart MDI products - Guardian™ Connect, InPen and i-Port Advance™ injection port

Get started with Smart MDI!


Complete this form and you'll hear from us soon.

Which product are you interested in learning more about? (please check the boxes below)

* indicates fields that are required


How can we communicate with you?

I have read and understood the terms of this marketing authorization. I authorize Medtronic to use my protected health information for the purposes described in the authorization.

HIPAA MARKETING AUTHORIZATION FOR USE OF PROTECTED HEALTH INFORMATION

Medtronic Diabetes* respects the privacy of all our customers. With your permission, we may use your protected health information, including your contact information and health-related data, for marketing purposes, promotional offers, survey opportunities, and advertising that we think may be of interest to you. We may also share your information with Medtronic Diabetes representatives and contractors.  

Please note that this Authorization is optional, and you may refuse to opt in.  If you do not want to opt in, it will not affect your treatment, health insurance eligibility, or benefits, and you will not be stopped or prevented from accessing the CareLink™ Personal system, or other Medtronic Diabetes products, mobile apps, or services. You will be provided with a copy of this Authorization after it is acknowledged.

This Authorization will expire ten (10) years from the date you submit this authorization online but may expire sooner if required by applicable law, or if you remove it by following one of the methods below:

  1. E-mail takecontrol@medtronic.com
  2. Sign in to the Profile page and update your communication preferences at www.Diabetes.shop/communication
  3. Contact Customer Service Center at 800-646-4633

Opting out will not affect actions Medtronic Diabetes has already taken based on this Authorization. Information disclosed pursuant to this Authorization may be re-disclosed by the recipient of the information and may no longer be protected by federal privacy standards. If you have additional questions about this Authorization, please contact our Customer Service Center at 800-646-4633 or by email at takecontrol@medtronic.com.

Please review our Notice of Privacy Practices and Privacy Statement or contact our support team to get details on how Medtronic Diabetes processes your personal data, the involvement of affiliates and third-party data processors, cross-border transfer, and your rights as a data subject.

*MiniMed Distribution Corp. and Medtronic MiniMed, Inc. are “Medtronic Diabetes”

I agree to receive phone calls and/or artificial prerecorded marketing voice messages sent from or on behalf of Medtronic Diabetes using automated technology at the phone number(s) I have provided.

CONSENT FOR RECEIPT OF PHONE COMMUNICATIONS

You consent to receiving phone calls, including pre-recorded and auto-dialed communications, at the phone number(s) submitted above using automated technology from or on behalf of MiniMed Distribution Corp. and its business associate Medtronic MiniMed, Inc. (collectively “Medtronic Diabetes”), concerning the marketing, advertising and/or offers of sale of Medtronic Diabetes products, therapies and services. You also certify that you are (a) age 18 and older and (b) authorizing and consenting to use of the information provided for Medtronic Diabetes to contact you. Your consent is not a condition for purchase. Airtime, message and data rates may apply. You may opt out at any time by (i) e-mailing takecontrol@medtronic.com; or (ii) signing into your myHome profile and updating your communication preferences (www.diabetes.shop/communication).

I agree to receive marketing SMS text communications using automated technology sent from or on behalf of Medtronic Diabetes at the mobile phone number(s) I have provided (message frequency may vary).

CONSENT FOR RECEIPT OF TEXT COMMUNICATIONS

You consent to receiving text messages at the phone number(s) submitted above using automated technology from or on behalf of MiniMed Distribution Corp. and its business associate Medtronic MiniMed, Inc. (collectively “Medtronic Diabetes”), concerning the marketing, advertising and/or offers of sale of Medtronic Diabetes products, therapies and services. You also certify that you are (a) age 18 and older and (b) authorizing and consenting to use of the information provided for Medtronic Diabetes to contact you. Your consent is not a condition for purchase. Airtime, message and data rates may apply. You may opt out at any time by (i) texting "STOP" in return to a text; (ii) sending an email to takecontrol@medtronic.com; or (iii) signing into your myHome profile and updating your communication preferences (www.diabetes.shop/communication).



Life with InPen and the Guardian Connect CGM—Sarah’s Story

Play button to watch Sarah video Image of Sarah walking her dog

Sarah

Lives with type 1 diabetes and was diagnosed as a young adult.


Meet Sarah


Compensated for her time. Thoughts and opinions are her own.

References
* Alerts must be set to receive predictive alerts
** Based on 150 injections per month versus 10 insertions per month
† Proper settings and user interaction required, including manual logging of rapid-acting insulin given by other means. WARNING: not doing so may lead to hypoglycemia, which could result in serious injury or death.

The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Medtronic is under license.

Important Safety Information: Guardian Connect CGM System
The Guardian Connect system requires a prescription and is indicated for continuous or periodic monitoring of glucose levels in the interstitial fluid under the skin, in patients (14 to 75 years of age) with diabetes mellitus. The system is intended to complement, not replace, information obtained from standard blood glucose monitoring devices, and is not recommended for people who are unwilling or unable to perform a minimum of two meter blood glucose tests per day, or for people who are unable or unwilling to maintain contact with their healthcare professional. The system requires a functioning mobile electronic device with correct settings. If the mobile device is not set up or used correctly, you may not receive sensor glucose information or alerts. For complete details of the system and its components, including warnings, contraindications, and precautions, please consult the user guides and important safety information.

Important Safety Information: InPen
The InPen is a home- use reusable pen injector for single- patient use by people with diabetes under the supervision of an adult caregiver, or by a patient age 7 and older for the self- injection of a desired dose of insulin and for calculating an insulin dose or carbohydrate intake based on user entered data. A healthcare professional must assist in dosage programming of the device prior to use, based on various patient- specific criteria and targets. The InPen requires a prescription. For additional product and safety information, please consult the Instructions for Use and bit.ly/InPenRisks.com.

Safety Information: i-Port Advance injection port
i-Port Advance injection port is indicated for patients who administer or receive multiple daily subcutaneous injections of physician prescribed medications, including insulin. The device may remain in place for up to 72 hours to accommodate multiple injections without the discomfort of additional needle sticks. i-Port Advance injection port may be used on a wide range of patients, including adults and children. For more, please see important safety information.